Pall Integrated Solutions for Gene Therapy
Pall have technologies that enable production of viral vectors on a production scale in a relatively small footprint. The statement holds true for both AAV and lent virus. The talk will cover both upstream and downstream technologies starting with seed train all the way through to the final formulation and filling step. With regards to bioreactors we will cover both adherent cell and suspension cell capabilities and projected future movements in the field. We will touch on process development services (PDS) where Pall are able to bring all of their expertise in continuous intensified process development to shorten the path to market for gene therapies.
Rick Morris, Ph.D.
Senior Vice President, R&D
Dr. Rick Morris has held many senior-level positions within both the Life Sciences and Industrial lines of business at Pall Corporation, gaining experience in the biopharmaceutical, medical, food & beverage and laboratory markets during his 30-year tenure. In September 2017, he was appointed as a senior vice president of R&D for Pall, which combines both single use technologies and biopharmaceutical groups, with a specific focus on the rapidly growing field of continuous bioprocessing. In this role Dr. Morris leads internal and external research and development projects on a global basis. He is based in Westborough, MA, USA and has R&D teams in the USA, UK and Belgium.
Pall Biotech Integrated Solutions for Gene Therapy
Biotech | Pall Corporation webinar series
Meet the authors from the ‘Insights on Successful Gene Therapy Manufacturing and Commercialization’ ebook